Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany

por Menzen, Markus, Berentzen, Tina Landsvig, Catarig, Andrei-Mircea, Pieperhoff, Sebastian, Simon, Jörg, Jacob, Stephan
Publicado 2023

Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study

por Bellido, Virginia, Abreu Padín, Cristina, Catarig, Andrei-Mircea, Clark, Alice, Barreto Pittol, Sofía, Delgado, Elias
Publicado 2022

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes

por Lingvay, Ildiko, Catarig, Andrei-Mircea, Lawson, Jack, Chubb, Barrie, Gorst-Rasmussen, Anders, Evans, Lyndon Marc
Publicado 2022

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study

por Holmes, Patrick, Bell, Heather Elizabeth, Bozkurt, Karan, Catarig, Andrei-Mircea, Clark, Alice, Machell, Alena, Sathyapalan, Thozhukat
Publicado 2021

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

por Lingvay, Ildiko, Capehorn, Matthew S, Catarig, Andrei-Mircea, Johansen, Pierre, Lawson, Jack, Sandberg, Anna, Shaw, Robert, Paine, Abby
Publicado 2020

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses

por Pratley, Richard E, Aroda, Vanita R, Catarig, Andrei-Mircea, Lingvay, Ildiko, Lüdemann, Jörg, Yildirim, Emre, Viljoen, Adie
Publicado 2020

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study

por Wolffenbuttel, Bruce H. R., Brugts, Michel P., Catarig, Andrei-Mircea, Clark, Alice, Kok, Maarten, Lieverse, Aloysius G., van Soest, Jaap
Publicado 2022

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

por McCrimmon, Rory J., Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Thielke, Desirée, Lingvay, Ildiko
Publicado 2020

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg

por Pratley, Richard E., Catarig, Andrei‐Mircea, Lingvay, Ildiko, Viljoen, Adie, Paine, Abby, Lawson, Jack, Chubb, Barrie, Gorst‐Rasmussen, Anders, Miresashvili, Nino
Publicado 2021

Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study

por Yale, Jean‐François, Catarig, Andrei‐Mircea, Grau, Katrine, Harris, Stewart, Klimek‐Abercrombie, Agnieszka, Rabasa‐Lhoret, Rémi, Reardon, Laura, Woo, Vincent, Liutkus, Joanne
Publicado 2021

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

por Yale, Jean-François, Bodholdt, Ulrik, Catarig, Andrei-Mircea, Catrina, Sergiu, Clark, Alice, Ekberg, Neda Rajamand, Erhan, Umut, Holmes, Patrick, Knudsen, Søren Tang, Liutkus, Joanne, Sathyapalan, Thozhukat, Schultes, Bernd, Rudofsky, Gottfried
Publicado 2022